Skip to main content

Alpha1-antitrypsin Deficiency clinical trials at UC Davis

1 research study open to eligible people

Showing trials for
  • Experimental Treatment with GLASSIA in Patients With Low A1PI Levels (condition where certain enzymes attack healthy lung tissue)

    “This study is being conducted to look at how well the study drug is able to increase your A1PI levels.”

    open to eligible people ages 18 years and up

    The purpose of the study is 2-fold: (1) to evaluate the safety and potential immunogenicity of GLASSIA following intravenous (IV) administration via in-line filtration; and (2) to assess the effects of GLASSIA augmentation therapy on the levels of A1PI and various biomarkers in the epithelial lining fluid (ELF) following intravenous (IV) administration at a dosage of 60 milligrams per kilogram (mg/kg) Body weight (BW)/week active alpha1-proteinase inhibitor (A1PI) protein for 25 weeks in participants with emphysema due to congenital A1PI deficiency.

    Sacramento, California and other locations

Last updated: